SEARCH RESULTS

329684 RESULTS

Apo A I

ANTIBODY polyclonal manufacturer Cat# ab20453 immunogen = purified mouse apolipoprotein AI from pooled mouse plasma high density lipoprotein liquid, affinity purified, Tris, EDTA, azide Apo A I <em>not</em> human; others not tested IgG Apolipoproteins

Apo A I

ANTIBODY polyclonal manufacturer Cat# ab7614 immunogen = full length native apoLipoprotein Type A-I (purified) liquid, affinity purified, azide Apo A I. Negligible cross with Type A-II, B, C-I, C-II, C-III, E and J others not tested IgG Apolipoproteins Abcam Goat

Apo A I

ANTIBODY polyclonal manufacturer Cat# ab7613 immunogen = full length native apoLipoprotein Type A-I (purified) liquid, affinity purified, azide Apo A I. Negligible cross with Type A-II, B, C-I, C-II, C-III, E and J others not tested IgG Apolipoproteins Abcam Goat

APP (DE2B4)

ANTIBODY monoclonal DE2B4 manufacturer Cat# AB35064 immunogen = synthetic peptide corresp. to residues 1-17 of Human Amyloid Precursor Protein liquid, protein-G, BSA, TBS, azide, Biotin conj. recognizes Amyloid Precursor Protein (APP) others not tested IgG<sub&

APP

ANTIBODY polyclonal manufacturer Cat# ab15272 immunogen = synthetic peptide (H M N V Q N G K W D S D P S G T K T C) corresp. to N-terminal aa 44-62 of human APP liquid, PBS, BSA, azide, affinity purified recognizes APP (β-APP770) and is predicted to recognize β-AP

Beka Solomon on Immunotherapy Update: Toward Patches and Creams

COMMENT The skin is a well-established effective route for vaccination. The authors evaluate the efficacy of transcutaneous immunization of PSAPP Tg mice in reducing cerebral amyloidosis using aggregated Aβ1-42 plus cholera toxin. Reduction in cerebral amyloidosi

Current Filters

  • Date Range : All x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE